2017

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.

Fagerholm R, Khan S, Schmidt MK, García-Closas M, Heikkilä P, Saarela J, Beesley J, Jamshidi M, et al. Oncotarget. 2017 Mar 14;8(11):18381-18398. doi: 10.18632/oncotarget.15110.